Startseite>>Signaling Pathways>> Neuroscience>> Dopamine Receptor>>Trimethobenzamide hydrochloride (Ro 2-9578)

Trimethobenzamide hydrochloride (Ro 2-9578) (Synonyms: Ro 2-9578)

Katalog-Nr.GC33527

Trimethobenzamidhydrochlorid (Ro 2-9578) ist ein Blocker des D2-Rezeptors.

Products are for research use only. Not for human use. We do not sell to patients.

Trimethobenzamide hydrochloride (Ro 2-9578) Chemische Struktur

Cas No.: 554-92-7

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
91,00 $
Auf Lager
100mg
82,00 $
Auf Lager
200mg
138,00 $
Auf Lager
500mg
276,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Trimethobenzamide hydrochloride is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.

Trimethobenzamide is a (non-phenothiazine) benzamide antiemetic that acts centrally to block D2 receptors, thereby inhibiting the medullary chemoreceptor trigger zone by blocking emetic impulses to the vomiting center[1].

The oral bioavailability of Trimethobenzamide is 60% to 100%. The time to peak is about 45 minutes after oral administration and; Intramuscular (I.M.) administration about 30 minutes after intramuscular administration[1].

[1]. Smith HS, et al. Dopamine receptor antagonists. Ann Palliat Med. 2012 Jul;1(2):137-42.

Bewertungen

Review for Trimethobenzamide hydrochloride (Ro 2-9578)

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Trimethobenzamide hydrochloride (Ro 2-9578)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.